Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 5:33 PM
Ignite Modification Date:
2025-12-24 @ 5:33 PM
NCT ID:
NCT07257068
Brief Summary:
To find out if taking a drug called infliximab (the "study drug") is safe and effective in reversing insulin dependence in CIADM.
Detailed Description:
Primary Objective
1\. To estimate the efficacy of infliximab in reversing insulin dependence in CIADM.
Secondary Objective
1. To evaluate the safety of infliximab when used for CIADM.
2. To estimate the duration of time off insulin for patients who are able to discontinue insulin.
Study:
NCT07257068
Study Brief:
Protocol Section:
NCT07257068